reports
Transactions under Novonesis’ share buyback program
Transactions under Novonesis’ share buyback program As of June 20th, 2025, Novonesis has purchased an accumulated 1,660,344 shares with a transaction value of DKK 713,0 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and initiated on March 5, 2025. Under the program, Novonesis will buy back B shares worth up to EUR 100 million (DKK 746 million) in total during the remainder of 2025. Please read the full announcement in PDF Attachment
Major shareholder announcement
Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 19, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,343,678 shares, corresponding to 4.98% (previously 5.02%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments i...
Major shareholder announcement
Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 16, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,532,753 shares, corresponding to 5.02% (previously 4.85%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments i...
Major shareholder announcement
Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 10, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 22,753,631 shares, corresponding to 4.85% of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments is 5.00% (previously...
Novonesis completes acquisition of dsm-firmenichs’s share of the Feed ...
Novonesis completes acquisition of dsm-firmenichs’s share of the Feed Enzyme Alliance Novonesis has successfully completed the acquisition of dsm-firmenich’s share of the Feed Enzyme Alliance following the satisfaction of all closing conditions. The acquisition was initially announced on February 11, 2025 (announcement No 2). Please read the full announcement in PDF. Attachment
Combining EVP roles of Human Health Biosolutions and Strategy & Integr...
Combining EVP roles of Human Health Biosolutions and Strategy & Integration As a next step on Novonesis’ integration journey, we combine the two EVP areas Human Health Biosolutions and Strategy & Integration. COPENHAGEN, Denmark – After successfully combining into one company, Novonesis is delivering strong results, progressing firmly on the integration, as well as realizing synergies across the company. As a next step on our integration journey, the EVP area of Strategy & Integration will combine with the Human Health Biosolutions sales area. Henrik Joerck Nielsen, currently Executive Vi...
Novonesis delivered a strong Q1 with 11% organic growth and confirms f...
Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook. The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter. Ester Baiget, President & CEO, say...
Interim report Q1 2025
Interim report Q1 2025 Strong start to the year and confirmed full-year outlook Ester Baiget, President & CEO: “We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. Growth was driven by strong innovation especially in emerging markets, and with a continued broad pull for our solutions in developed markets. Synergies are materializing as expected and we are confirming the full-year outlook. We continue to see solid demand across the business, and our regional presence and resilient global setup enable us to respond with...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.